Teva Pharmaceutical Industries Ltd
featured
Check out which companies are making headlines after the bell Tuesday:
» Read More
More
-
NEW YORK-- Teva Pharmaceutical Industries Ltd. said Monday that it is buying MicroDose Therapeutx for $40 million to build its pipeline of respiratory products. Teva, based in Israel, is one of the world's largest makers of generic drugs. U.S.-traded shares of Teva added 20 cents to $39.28 in Monday afternoon trading.
-
Judge Edward Korman of the U.S. District Court in Brooklyn, New York, said the FDA proposal was "sufficient" to comply with his order to make emergency contraception widely available.
-
HERZLIYA, Israel, June 6- Inspired by its success in high-tech electronics and software, Israel is hoping to pull off the same trick in life sciences. High-tech has been one of Israel's main growth engines and companies such as Intel Inc, IBM and Google Inc have major R&D centres in the country.
-
District Judge Edward Korman in Brooklyn said he would give the FDA until May 13 to ask a federal appeals court in Manhattan to stay the order, which had been scheduled to take effect on Friday.
-
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
-
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
-
District Judge Edward Korman on April 5 ordered the FDA to lift age restrictions on all levonorgestrel-based emergency contraception- also known as the "morning-after" pill or "Plan B"- to prevent unwanted pregnancies. The FDA has appealed the ruling to the 2nd U.S. Circuit Court of Appeals in Manhattan.
-
Lawyers with the Justice Department filed the appeal with the 2nd U.S. Circuit Court of Appeals in New York, according to court documents. District Judge Edward Korman's ruling from April 5 that required the FDA to make the emergency contraception available over-the-counter to women of all ages within 30 days.
-
Lawyers with the Justice Department filed the appeal with the 2nd U.S. Circuit Court of Appeals in New York, according to court documents. District Judge Edward Korman's ruling from April 5 that required the FDA to make the emergency contraception available over-the-counter to women of all ages within 30 days.
-
May 1- Drugs from Amgen Inc, Teva Pharmaceutical Industries and Sanofi that boost white blood cells are being evaluated by U.S. regulators as treatments for radiation exposure caused by a nuclear attack or accident.
-
The FDA said on Tuesday it will allow girls as young as 15 years old to buy without a prescription the Plan B One-Step emergency contraceptive, made by a unit of Teva Pharmaceutical Industries Ltd..
-
The FDA has lowered the age limit for Plan B One-Step emergency contraceptive to 15. The pill will be available without a prescription and stocked on store shelves.
-
.160x105.jpg?v=1366904651 "Fed May Provide a Safety Net for the Market")
The Fed is expected to repeat its dovish message in the coming week, which could provide a safety net for the market amid a big wave of earnings and the April jobs report.
-
The "Mad Money" host puts this pharmaceutical stock on the "Sell Block."
-
1999: Teva Pharmaceutical Industries Ltd receives FDA approval to market Plan B, the first emergency contraceptive drug for prescription-only use in the United States. 2005: Reproductive-rights groups file lawsuit in Brooklyn federal court seeking to force FDA to respond to their petition.
-
April 2- Neurological and dermatology drugs maker Merz Pharma Group offered to buy cosmetic products maker Obagi Medical Products Inc for $383.5 million, topping a bid by Canada's Valeant Pharmaceuticals International Inc. Merz's $22- per-share bid represents a premium of 11 percent to Valeant's offer of $19.75.
-
WASHINGTON, March 29- Biogen Idec Inc said on Friday it will charge $54,900 a year for its multiple sclerosis drug, Tecfidera, which received U.S. approval on Wednesday. The company has priced the drug at a discount to key competitors such as Novartis AG's MS pill Gilenya, which costs roughly $60,000 a year, in a bid to maximize its market share.
-
*Sales of Tecfidera expected to top $3 billion by 2017. WASHINGTON, March 27- U.S. regulators on Wednesday approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with annual sales topping $3 billion.
-
*Sales of Tecfidera expected to top $3 billion by 2017. March 27- U.S. regulators have approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with annual sales of more than $3 billion.
-
Spending on drugs to treat common diseases fell 1.5 percent among customers who receive prescription benefits through commercial insurers.
Most Popular Video
DuckDuckGo CEO Gabriel Weinberg says web traffic on his search engine, billed as an alternative to Google that doesn't store your private information, surged 33 percent after the NSA news broke. Weinberg discusses the model of his search engine, and how the company makes money.
Wednesday, 19 Jun 2013 | 6:31 AM ETJohn Silvia, Wells Fargo Securities, and Barbara Marcin, Gabelli Dividend Income Fund, discuss whether investors should reconsider allocating their portfolios as the Fed wraps up its two-day policy meeting.
Wednesday, 19 Jun 2013 | 8:53 AM ETKen Langone, Invemed Associates chairman and president, called Fed Chairman Ben Bernanke a "lame duck."